Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting
28. April 2023 08:15 ET
|
Processa Pharmaceuticals, Inc.
PCS12852 Shown to be Safe and Efficacious in Phase 2 Proof-of-Concept Trial in Gastroparesis PatientsPCS12852 Improved Both Gastroparesis Symptom Scores and Gastric Emptying Rate HANOVER, MD, April ...
PCS12852 Improves Gastric Emptying in Gastroparesis Patients
08. November 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
In a Phase 2A Proof-of-Concept trial, the Gastric Emptying Breath Test (GEBT) results demonstrated statistical improvement in gastric emptying in gastroparesis patients receiving 0.5 mg of PCS12852 (6...
Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs
15. September 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
PCS12852 for Gastroparesis concluded enrollment a month ahead of schedule. Statistics on gastric emptying, safety and GEBT data will be available by the end of October and full topline data is...
Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022
07. September 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality...
Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST
05. Mai 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, May 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST
23. März 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 23, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality...
Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
12. August 2021 17:15 ET
|
Processa Pharmaceuticals, Inc.
Adds fourth clinical asset, RX-3117, and targets major milestones in the second half of 2021 HANOVER, Md., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a...
Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
20. Mai 2021 16:05 ET
|
Processa Pharmaceuticals, Inc.
~Processa’s trial is currently enrolling patients with ulcerated Necrobiosis Lipoidica. Detailed information on the trial can be located on clinicaltrials.gov NCT#: 04800562.~ HANOVER, MD., May 20,...
Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET
22. März 2021 09:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., March 22, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...